(Total Views: 635)
Posted On: 11/20/2021 11:14:28 AM
Post# of 149219
very interesting thought.
it would explain the "out of the blue" research coverage by Citi. That still confuses me - unless, Citi had to come up to speed on CytoDyn for some specific reason. Otherwise, there is no way on earth that they would randomly pick a pre-revenue OTC biotech to cover.
I would fully support a partnership that would accelerate our path to realizing the potential of this drug.
it would explain the "out of the blue" research coverage by Citi. That still confuses me - unless, Citi had to come up to speed on CytoDyn for some specific reason. Otherwise, there is no way on earth that they would randomly pick a pre-revenue OTC biotech to cover.
I would fully support a partnership that would accelerate our path to realizing the potential of this drug.
(5)
(0)Scroll down for more posts ▼
